Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

Autor: Jaouad Azzahhafi, Thomas O. Bergmeijer, Wout W. A. van den Broek, Dean R. P. P. Chan Pin Yin, Senna Rayhi, Joyce Peper, Willem L. Bor, Daniel M. F. Claassens, Ron H. N. van Schaik, Jurriën M. ten Berg

Publikováno v: Frontiers in Pharmacology, Vol 13 (2022)

Aims: To determine the clinical efficacy, adverse events and side-effect dyspnea of CYP3A4*22 and CYP3A5 expressor status in ticagrelor treated patients.Methods and results: Ticagrelor treated patients from the POPular Genetics randomized controlled

Externí odkaz: https://doaj.org/article/7ac9d46665ce483189d6a3185410c1aa

Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment

Autor: Thomas O. Bergmeijer, Mathijs van Oevelen, Paul W. A. Janssen, Thea C. Godschalk, Robert A. Lichtveld, Johannes C. Kelder, Michiel Voskuil, Arend Mosterd, Gilles Montalescot, Jurriën M. ten Berg

Publikováno v: TH Open, Vol 02, Iss 04, Pp e357-e368 (2018)

Abstract Objectives The objective of this registry was to study the safety of prehospital initiation of ticagrelor compared with clopidogrel. Background Ticagrelor has replaced clopidogrel in many hospitals as the routinely used antiplatelet drug

Externí odkaz: https://doaj.org/article/401a87929a5842ebbf3407cb620d1790

Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

Autor: Richard M. Tjon Joe Gin, Emanuele Barbato, Thomas O. Bergmeijer, Arnoud W J van 't Hof, Pim W. M. van Dorst, Daniel M.F. Claassens, Arend Mosterd, Vera H.M. Deneer, Renicus S Hermanides, Carmine Morisco, Folkert W. Asselbergs, Willem Dewilde, Gerrit J.A. Vos, C. Boersma, Pim van der Harst, Jean-Paul R. Herrman, Jurriën M. ten Berg, Maarten J. Postma

Publikováno v: American Journal of Cardiovascular Drugs, 22(2), 195-206. Adis International Ltd
American journal of cardiovascular drugs, 22(2), 195-206. ADIS INT LTD

INTRODUCTION: The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2Y12 inhibitor strategy reduced bleeding rates compared with standard treatment with ticagrelor or prasugrel without increasing thrombotic event rates after primary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524e9c700d35d5b49880db1ea1289396
http://hdl.handle.net/11588/857926

Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients

Autor: Michiaki Kubo, Tobias Geisler, Dimitrios Alexopoulos, Gian Franco Gensini, Kiyuk Chang, Jean-Luc Reny, Joshua P. Lewis, Meinrad Gawaz, Elke Schaeffeler, Kevin P. Bliden, Stefan Winter, Eun Young Kim, Ruth E. Pakyz, Paul A. Gurbel, Rossella Marcucci, Israel Fernandez-Cadenas, Joan Montaner, Nadia Paarup Dridi, Li Gong, Jae-Gook Shin, Matthias Schwab, Ryan Whaley, Jurriën M. ten Berg, John H. Cleator, Pierre Fontana, Marco Valgimigli, Russ B. Altman, Ho-Sook Kim, Joshua D. Backman, Jolanta M. Siller-Matula, Daniel Aradi, Braxton D. Mitchell, Betti Giusti, Thomas O. Bergmeijer, Kathleen A. Ryan, Alan R. Shuldiner, Ming-Shien Wen, Jean-Pierre Déry, Marylyn D. Ritchie, Teri E. Klein, Dan M. Roden, Ming Ta Michael Lee, Dietmar Trenk, Gianluca Campo, Lene Holmvang, Willibald Hochholzer

Publikováno v: Eur Heart J Cardiovasc Pharmacother

Aims Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants of inter-individual variability in on-treatment platelet inhibition (e.g. CYP2C19*2), evidence that these variants

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2617daa4da32047436b6779da7ddfbcb
https://doi.org/10.1093/ehjcvp/pvz045

Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype A POPular Genetics Subanalysis

Autor: Vera H.M. Deneer, Renicus S Hermanides, Carmine Morisco, Richard M. Tjon Joe Gin, Gerrit J.A. Vos, Arend Mosterd, Pim van der Harst, Daniel M.F. Claassens, Jean-Paul R. Herrman, Johannes C. Kelder, Willem Dewilde, Paul W.A. Janssen, Bakhtawar K. Mahmoodi, Arnoud W J van 't Hof, Jurriën M. ten Berg, Folkert W. Asselbergs, Thomas O. Bergmeijer, Emanuele Barbato

Publikováno v: Circulation-Cardiovascular interventions, 14(4):009434, 402-411. LIPPINCOTT WILLIAMS & WILKINS
Circulation. Cardiovascular interventions, 14(4). Lippincott Williams and Wilkins
Circulation: Cardiovascular Interventions, 14(4), 402. Lippincott Williams and Wilkins Ltd.
Circulation-Cardiovascular Interventions, 14(4):009434, 402-411. LIPPINCOTT WILLIAMS & WILKINS

Background: Guidelines favor ticagrelor or prasugrel over clopidogrel in patients with myocardial infarction. However, the POPular Genetics trial (Patient Outcome After Primary Percutaneous Coronary Intervention [PCI]) showed that in patients with pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54ef6016a26fcea7ac724e7cf6c3723
https://research.rug.nl/en/publications/c88d7bed-0522-46be-abfa-3331f07b3fe4